Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

gevokizumab

An IgG2 humanized monoclonal antibody against the pro-inflammatory cytokine interleukin 1 beta (IL-1b) with anti-inflammatory activity. Gevokizumab binds to IL-1b, thereby preventing IL-1b-mediated inflammatory responses. This antibody has a long half life and allows for once a month dosing intervals.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:immunoglobulin G2, anti-(human interleukin 1-beta) (human-Mus musculus XOMA 052 heavy chain), disulfide with human-Mus musculus XOMA 052 kappa-chain, dimer
Code name:XOMA 052
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search